Literature DB >> 19328446

Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients.

James W Simpkins1, Joshua W Gatson, Jane G Wigginton.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19328446      PMCID: PMC5008237          DOI: 10.1016/j.jalz.2009.01.013

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  46 in total

1.  Do silent brain infarctions predict the development of dementia after first ischemic stroke?

Authors:  N M Bornstein; A Y Gur; T A Treves; I Reider-Groswasser; B D Aronovich; S S Klimovitzky; D Varssano; A D Korczyn
Journal:  Stroke       Date:  1996-05       Impact factor: 7.914

2.  Poststroke dementia: incidence and relationship to prestroke cognitive decline.

Authors:  H Hénon; I Durieu; D Guerouaou; F Lebert; F Pasquier; D Leys
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

3.  Brain trauma in aged transgenic mice induces regression of established abeta deposits.

Authors:  Y Nakagawa; L Reed; M Nakamura; T K McIntosh; D H Smith; K E Saatman; R Raghupathi; J Clemens; T C Saido; V M Lee; J Q Trojanowski
Journal:  Exp Neurol       Date:  2000-05       Impact factor: 5.330

4.  Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

Authors:  Richard E Hartman; Helmut Laurer; Luca Longhi; Kelly R Bales; Steven M Paul; Tracy K McIntosh; David M Holtzman
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

Review 5.  Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?

Authors:  Benedict C Albensi; Chiazor Igoechi; Damir Janigro; Erin Ilkanich
Journal:  Am J Alzheimers Dis Other Demen       Date:  2004 Sep-Oct       Impact factor: 2.035

6.  Mild head injury increasing the brain's vulnerability to a second concussive impact.

Authors:  H L Laurer; F M Bareyre; V M Lee; J Q Trojanowski; L Longhi; R Hoover; K E Saatman; R Raghupathi; S Hoshino; M S Grady; T K McIntosh
Journal:  J Neurosurg       Date:  2001-11       Impact factor: 5.115

7.  Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication.

Authors:  S Fleminger; D L Oliver; S Lovestone; S Rabe-Hesketh; A Giora
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

Review 8.  Caspase-3 cleavage of GGA3 stabilizes BACE: implications for Alzheimer's disease.

Authors:  Robert Vassar
Journal:  Neuron       Date:  2007-06-07       Impact factor: 17.173

9.  Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity.

Authors:  Giuseppina Tesco; Young Ho Koh; Eugene L Kang; Andrew N Cameron; Shinjita Das; Miguel Sena-Esteves; Mikko Hiltunen; Shao-Hua Yang; Zhenyu Zhong; Yong Shen; James W Simpkins; Rudolph E Tanzi
Journal:  Neuron       Date:  2007-06-07       Impact factor: 17.173

10.  Increased beta-secretase activity and expression in rats following transient cerebral ischemia.

Authors:  Yi Wen; Otuonye Onyewuchi; Shaohua Yang; Ran Liu; James W Simpkins
Journal:  Brain Res       Date:  2004-05-29       Impact factor: 3.252

View more
  3 in total

1.  New hope for survivors of stroke and traumatic brain injury.

Authors:  Ian Clark
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

Review 2.  Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases.

Authors:  I A Clark; B Vissel
Journal:  Br J Pharmacol       Date:  2018-09-06       Impact factor: 9.473

Review 3.  Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.

Authors:  I A Clark; B Vissel
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.